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Fig 1. National Inpatient Sample (NIS) carotid artery stenting (CAS;
moving average). CMS, Centers for Medicare and Medicaid Services;
CREST, Carotid Revascularization Endarterectomy vs. Stent Trial.
Fig 2. Vascular Study Group of New England (VSGNE): carotid artery
stenting (CAS; moving average). CMS, Centers for Medicare and Medicaid
Services; CREST, Carotid Revascularization Endarterectomy vs. Stent Trial.
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Objectives: Vascular access thrombosis (VAT) is a severe complica-
tion that needs a timely treatment. The annual incidence of VAT and the
timeliness of its treatment are not currently known.
Methods: A comprehensive survey of all the nephrologists stafﬁng
all hemodialysis centers in France was performed during March and April
2013. The number of patients, percentage of permanent or temporary
catheter use, incidence of VAT, specialty of the referral physician con-
sulted to treat VAT, and mean time to treatment were recorded for
each center. Data were compared between rural and urban zones of
each center.
Results: A total of 266 of 269 centers (99%) participated, with 114
private centers, 118 hospitals, and 37 academic hospitals treating 32,461 he-
modialysis patients. A total of 27,798 patients (85%) used an arteriovenous
(AV) ﬁstula or graft, and 4663 (15%) required a permanent catheter. In 104
centers treating 11,088 patients with AV ﬁstula or grafts, there were 905
documented episodes of VAT (8.2%) in 1 year; in the other 162 centers
that supplied a range, the mean incidence of VAT was 8.5%. Immediately
after diagnosis, 8% of the centers routinely placed a temporary catheter,
and 26% never placed any catheter. Fifty-three percent of centers refer
VAT to a vascular surgeon (VS) and 32% to an interventional radiologist
(IR), with only 2% to urology and 13% variable referral depending on
case complexity. There was a difference in referral patterns between rural
(VS, 75%; IR, 25%) and urban centers (VS, 49%; IR, 51%). Time to treat-
ment was <24 hours in 58% of the centers and <48 hours in 91% of the
centers; treatment >48 hours (9%) occurred predominantly in rural zones
(P ¼ .04). The specialty of the treating physician did not inﬂuence time
to treatment (P > .05).
Conclusion: The annual incidence of VAT is 8%, and 91% of cases in
France are treated #48 hours, consistent with European treatment guide-
lines. There is a disparity between rural and urban centers regarding the spe-
cialty of the treating physician. Increasing access to VSs may be an
alternative to regionalization of specialty care.
Disclosures: N. Sadaghianloo: Nothing to disclose; E. Jean-Baptiste:
Nothing to disclose; S. Declemy: Nothing to disclose; H. Gaïd: Nothing
to disclose; C. Robino: Nothing to disclose; A. Dardik: Nothing to
disclose; R. Hassen-Khodja: Nothing to disclose
Effects of Publications of Centers for Medicare and Medicaid Services
(CMS) Guidelines for Carotid Artery Stenting (CAS) and CREST
Results on National and Regional Utilization of CAS for Carotid
Revascularizationy
Mohammad H. Eslami,1 Denis Rybin,2 Gheorghe Doross,2 Alik Farber1.
1Boston University School of Medicine, Boston, Mass; 2Boston University
School of Public Health, Boston, Mass
Objectives: Since approval of carotid artery stenting (CAS), there
have been two seminal publications about CAS reimbursement (Centers
for Medicare and Medicaid Services, 2008) and results (Carotid Revascular-
ization Endarterectomy vs. Stent Trial [CREST], 2010). We explored
trends in CAS utilization after these publications nationally (National Inpa-
tient Sample [NIS]) among different specialties performing CAS and
regionally (Vascular Study Group of New England [VSGNE]) among
mostly vascular surgeons.
Methods: The most recent data sets of NIS and VSGNE were
queried for patients undergoing CAS using appropriate International
Classiﬁcation of Diseases-9th Edition codes. Utilization proportions of
CAS were calculated quarterly from 2005 to 2011 for NIS and from
2005 to 2013 for VSGNE. Three time intervals were selected Q1/
2005 to Q2/2008 (P1), Q2/2008 to Q3/2010 (P2), and after Q3/
2010 (P3) related to CMS guidelines and the CREST publication. Logis-
tic regression with terms modeling change in the odds ratio (OR) for the
second and third time intervals was used to estimate different trends in
CAS utilization for overall samples and for symptomatic and asymptom-
atic cases.>Eastern Vascular Society
yNew England Society for Vascular SurgeryResults: In the NIS sample, 95% of CAS was performed in asymptom-
atic patients vs 67% in the VSGNE data set. Overall CAS utilization was
higher nationally than regionally (12.51% in NIS vs 5.64% in VSGNE).
CAS was used more frequently for symptomatic patients in VSGNE
(6.36% vs 5.31%; P ¼ .032) and in NIS (19.12% vs 12.17%, P < .001) sam-
ples. Nationally, there were signiﬁcant increases in frequency of CAS in P1
(P < .001) and P3 (P ¼ .027), with a plateau during P2 (P ¼ .599). In
VSGNE, we observed an overall signiﬁcant decrease in CAS during P1
(P ¼ .004) and then signiﬁcant increases in CAS in P2 (P ¼ .036) and in
P3 (P ¼ .005). Fig 1 and Fig 2 summarize trends for the overall, symptom-
atic, and asymptomatic groups.
Conclusions: Overall use of CAS has increased since 2005 but was
not uniformly affected by CMS guidelines or the CREST publication.
The CAS use within VSGNE followed a more predictable pattern.
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Objectives: Vascular reconstruction can facilitate pancreas tumor
resection, but optimal methods of reconstruction are not well studied. We
analyzed our results for portal vein reconstruction (PVR) for pancreatic
resection and determinants of postoperative patency.>Eastern Vascular Society
Fig. A, Unadjusted outcomes and costs of endovascular aneurysm
repair (EVAR): 2000 to 2011. B, Adjusted outcomes and costs of
EVAR: 2009 to 2011 vs 2000 to 2002. CI, Conﬁdence interval; OR,
odds ratio.
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base of 6522 patients who underwent pancreatic resection at our hospital
from 1970 to 2014. A total of 128 patients had >6 months follow-up
with computed tomography imaging. Preoperative, intraoperative, and
postoperative factors were recorded. Patients with and without postopera-
tive PVR thrombosis were compared using univariate, multivariate, and
receiver-operating characteristic curve analyses.
Results: Patient survival was 100% at 1 month, 95% at 6 months,
83% at 1 year, and 54% on overall median follow-up of 194 days. Me-
dian survival was 14 6 26 months. Eighty-two percent of PVRs were
performed with a primary repair, 8.5% with interposition vein, 5.5%
with interposition prosthetic graft, and 4% with patch. PVR patency
was 100% at 1 day, 98% at 1 month, 91% at 6 months, and 83% at
1 year. Patients with PVR thrombosis were not signiﬁcantly different
from patients with a patent PVR in age, survival, preoperative comor-
bidities, tumor characteristics, perioperative blood loss or transfusion,
or postoperative complications. They were more likely to have preop-
erative chemotherapy (53% vs 9%, P ¼ .0001), radiation (35% vs 2%,
P ¼ .0001), prolonged operative time (610 6 91 vs 423 6 188 mi-
nutes, P ¼ .0001), and develop postoperative ascites (76% vs 22%,
P ¼ .0001). The number of patients who developed ascites in the
setting of tumor recurrence did not differ among those with throm-
bosed and patent PVR (38% vs 50%, P ¼ .7). Patients with PVR
thrombosis were more likely to have prosthetic graft placement than
patients with a patent PVR (18% vs 2.7%; odds ratio [OR], 7.7;
95% conﬁdence interval [CI], 1.4-42, P ¼ .03). PVR patency at
6 months was signiﬁcantly lower for graft reconstruction (0%)
compared with primary repair (95%, P ¼ .0004) and vein reconstruc-
tion (91%, P ¼ .04). On multivariate analysis, operative time (OR,
1.01; 95% CI, 1.01-1.02) and prosthetic graft placement (OR, 8.12;
95% CI, 1.1-74) were independent predictors of PVR thrombosis
(C statistic ¼ 0.88).
Conclusions: Long operative times and use of prosthetic grafts for
reconstruction are risk factors for postoperative portal vein thrombosis. Pri-
mary repair and vein interposition should be preferentially used for PVR in
the setting of pancreatic resection.
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Objectives: Early ﬁstula thrombosis (EFT) is a cause of autogenous
arteriovenous ﬁstula (AVF) failure. We followed up a cohort of men and
women with newly created AVFs to identify baseline predictors of EFT.
Methods: Cases of EFT, deﬁned as thrombosis diagnosed by physical
examination or ultrasound imaging, that occurred #16 days of AVF crea-
tion among participants of the Hemodialysis Fistula Maturation (HFM)
Study were compared with 166 non-EFT controls selected from the study.
They were optimally matched on ﬁve prespeciﬁed variables: gender, age (6
8 years), diabetes, dialysis status, and surgeon AVF volume within the prior
3 years (6 70 cases). Conditional logistic regression models were ﬁt with
and without adjustment for use of oral antithrombotic medication at
enrollment.
Results: Twenty-nine cases (5.3%) of EFT occurred among the ﬁrst
544 participants of a targeted enrollment of 600. Of the factors consid-
ered, the surgeon’s intraoperative perceptions were most strongly associ-
ated with EFT: maturation success (unlikely, marginal, likely) per
category (odds ratio [OR], 9.71; conﬁdence interval [CI], 3.7-25.5;yNew England Society for Vascular SurgeryP < .0001); absence vs presence of any intraoperative thrill (OR, 36.5;
CI, 4.2-320; P ¼ .0006); and the surgeon’s subjective frustration during
the procedure (OR, 6.99; CI, 2.38-20.5; P ¼ .0002). Longer duration
of surgery, which in both full and matched data sets was associated
with absence of thrill (2.0 vs 1.6 hours in the full data set), frustration
(2.3 vs 1.6 hours), and lower predicted likelihood of success (2.3 vs
1.7 vs 1.6 hours), was also itself predictive of EFT (OR, 2.0 per hour;
CI, 1.1-3.4; P ¼ .013). When present, a reduced extent of intraoperative
thrill (to the proximal, middle, or distal third of forearm/arm from the
ﬁstula) was also associated with EFT (OR per third of forearm/arm,
3.87; CI, 1.16-12.9; P ¼ .014). An intraoperative assessment that matu-
ration success was unlikely or that it was marginal when also combined
with surgeon frustration predicted 48% of EFTs with 98% speciﬁcity,
positive predictive value of 54%, and negative predictive value of 97%.
EFT was associated with forearm (vs upper arm) AVF (OR, 2.83; CI,
1.05-7.61; P ¼ .04). Oral antithrombotic medication was not signiﬁ-
cantly associated with EFT.
Conclusions: Although EFT was infrequent among HFM Study
participants, this outcome was common when the surgeon expressed
substantial intraoperative concern.
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Objectives: The purpose of this study was to characterize the
evolution in the “value” of endovascular abdominal aortic aneurysm
repair (EVAR) by detailing changes in adjusted outcomes and costs
over time.>Eastern Vascular Society
